• Bree Chancellor, Eytan Raz, Maksim Shapiro, Omar Tanweer, Erez Nossek, Howard A Riina, and Peter Kim Nelson.
• The Bernard and Irene Schwartz Neurointerventional Radiology Section, Center for Stroke and Cerebrovascular Diseases, New York University Langone Medical Center, New York, New York.
• Neurosurgery. 2020 Jan 1; 86 (Suppl 1): S36-S45.

AbstractFlow diverters (FDs) have changed the management of brain aneurysms; not only for complex aneurysms (giant, fusiform and blister) refractory to conventional therapies, but also for unruptured lesions previously managed by traditional surgical or coil-based endovascular methods. Since 2011 when the PipelineTM Embolization Device (Medtronic) was cleared by the Food and Drug Administration for adults with large or giant wide-neck intracranial aneurysms of the internal carotid artery proximal to the posterior communicating segment, the role of flow diversion for aneurysm treatment has expanded-supported by favorably low complication and high cure rates compared with alternative treatments. Here we review the key clinical trials and the long term outcomes that have demonstrated safety and efficacy of minimized porosity endoluminal devices in the treatment of cerebral aneurysms.Copyright © 2019 by the Congress of Neurological Surgeons.

23 keywords...

hide…